Officially launched in Barcelona on March 2, 2025, the CL1 system, known as Synthetic Biological Intelligence (SBI), is expected to significantly impact science and medical research.

This innovative system is designed to be more flexible and energy-efficient than traditional silicon-based AI chips, operating on just a few watts.

The use of human neurons in computing raises questions about the future of AI development, particularly regarding learning efficiency and energy consumption.

Cortical's approach could reduce reliance on animal testing for neurological and psychiatric drug development, addressing ethical concerns in research.

Dr. Brett Kagan, the chief science officer, emphasized the importance of navigating ethical dilemmas, ensuring that their systems do not create suffering or consciousness in artificial networks.

Unlike traditional AI, which requires vast amounts of power, the CL1 can learn quickly from limited data, mimicking biological intelligence.

The human-cell neural networks on the silicon chip evolve continually and learn more rapidly than existing silicon-based AI chips used in large language models.

Dr. Hon Weng Chong, founder and CEO of Cortical Labs, stated that the launch of CL1 is a significant milestone in democratizing access to advanced technology for researchers.

Cortical Labs aims to democratize access to this technology through a 'Wetware-as-a-Service' model, allowing researchers to either purchase the CL1 or rent access remotely.

The first CL1 units are expected to ship in June 2025, with a price tag of approximately $35,000 each.

Potential applications of the CL1 include revolutionizing drug discovery, disease modeling, and enhancing robotic intelligence, while also reducing the need for animal testing.

Cortical Labs has unveiled the CL1, the world's first commercial biological computer that integrates human brain cells with silicon hardware, creating adaptable neural networks.